UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Gritstone Bio Inc (GRTS)

Gritstone Bio Inc (GRTS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.0322 -0.0150 (-31.78%) 10/21/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.0322 unch (unch) -
Quote Overview for Mon, Oct 21st, 2024
Day Low
0.0310
Day High
0.0403
Open 0.0403
Previous Close 0.0472 0.0472
Volume 61,017,900 61,017,900
Avg Vol 52,407,121 52,407,121
Stochastic %K 0.44% 0.44%
Weighted Alpha -80.76 -80.76
5-Day Change -0.0218 (-40.37%) -0.0218 (-40.37%)
52-Week Range 0.0310 - 3.1700 0.0310 - 3.1700
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,496
  • Shares Outstanding, K 108,569
  • Annual Sales, $ 16,340 K
  • Annual Income, $ -138,490 K
  • EBIT $ -136 M
  • EBITDA $ -130 M
  • 60-Month Beta 0.49
  • Price/Sales 0.34
  • Price/Cash Flow N/A
  • Price/Book 0.16
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.09
  • Most Recent Earnings $-0.16 on 08/13/24
  • Next Earnings Date 11/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +57.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0310 +3.87%
on 10/21/24
Period Open: 0.6277
0.6600 -95.12%
on 09/23/24
-0.5955 (-94.87%)
since 09/20/24
3-Month
0.0310 +3.87%
on 10/21/24
Period Open: 0.6500
0.6946 -95.36%
on 07/23/24
-0.6178 (-95.05%)
since 07/19/24
52-Week
0.0310 +3.87%
on 10/21/24
Period Open: 2.0200
3.1700 -98.98%
on 01/16/24
-1.9878 (-98.41%)
since 10/20/23

Most Recent Stories

More News
Stocks Tread Water Before the Open as Investors Await Key U.S. GDP Data, Nike Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.04%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.05% this morning as market participants geared up for a flurry of U.S. economic data while also...

ZION : 43.82 (+2.14%)
PTON : 5.72 (+0.35%)
MU : 71.69 (+0.94%)
NQZ23 : 16,530.23s (-0.07%)
NKE : 54.72 (-1.25%)
GRTS : 0.0322 (-31.78%)
ACN : 290.58 (+0.27%)
RYA.I.DX : 19.600 (+1.34%)
WDAY : 233.62 (+0.55%)
NEE : 68.28 (+0.87%)
PAYX : 148.77 (-0.20%)
JBL : 134.96 (+0.82%)
Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

-- Expert in virology, immunology and vaccine development’s appointment effective August 12 --...

GRTS : 0.0322 (-31.78%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.0322 (-31.78%)
Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022

Conference call to occur at 4:30pm ET on August 4...

GRTS : 0.0322 (-31.78%)
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications

-- Results, which were previously pre-printed in bioRxiv, show Gritstone’s second-generation self-amplifying mRNA (samRNA) vaccine candidate drove broad...

GRTS : 0.0322 (-31.78%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.0322 (-31.78%)
Gritstone Earns 2022 Great Place to Work Certification™

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.0322 (-31.78%)
Gritstone to Participate in H.C. Wainwright Global Investment Conference

EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.0322 (-31.78%)
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data...

GRTS : 0.0322 (-31.78%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next...

GRTS : 0.0322 (-31.78%)

Business Summary

Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict...

See More

Key Turning Points

3rd Resistance Point 0.0473
2nd Resistance Point 0.0438
1st Resistance Point 0.0380
Last Price 0.0322
1st Support Level 0.0287
2nd Support Level 0.0252
3rd Support Level 0.0194

See More

52-Week High 3.1700
Fibonacci 61.8% 1.9709
Fibonacci 50% 1.6005
Fibonacci 38.2% 1.2301
Last Price 0.0322
52-Week Low 0.0310

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar